Infection News

Recent study data showed that concomitant chronic hepatitis B and nonalcoholic steatohepatitis were significantly more likely to lead to advanced fibrosis and liver-related outcomes including mortality compared with chronic hepatitis B alone.

Harvoni joins other direct-acting antivirals in demonstrating safety and high efficacy in younger pediatric patients with chronic hepatitis C, specifically those aged 3 years to younger than 6 years, according to results published in Hepatology.

With $7 million from the Patient-Centered Outcomes Research Institute, seven opioid treatment programs announced entry into an ongoing study of telemedicine for treatment of hepatitis C.

Researchers found that population density and water balance were key factors influencing the occurrence of hepatitis E outbreaks, according to a study published in Nature.

Researchers discovered fluoroquinolone-resistant Escherichia coli in 8.8% of fecal samples collected from healthy adult women with no recent documented UTI, mostly from two pandemic strains, according to findings published in Clinical Infectious Diseases.

Intent Solutions announced a partnership with the University of Kentucky in a $15 million federal grant program aimed at eliminating hepatitis C in an eastern Kentucky county that has particularly high rates of chronic infection, according to a press release.

Vibration-controlled transient elastography outperformed aspartate aminotransferase to platelet ratio index and Fibrosis-4 index as a noninvasive biomarker for advanced fibrosis in patients with hepatitis B and HIV coinfection, according to a study published in Hepatology.

Recent vomiting is the main source of airborne norovirus and a likely cause of outbreaks in health care facilities, according to study results published in Clinical Infectious Diseases.

The pangenotypic direct-acting antiviral Mavyret demonstrated 100% sustained virologic response in adolescent patients aged 12 years to 17 years with a safety profile consistent with adult patients, according results from part one of the DORA study.

Enanta Pharmaceuticals launched the first part of a phase 1a/b clinical study of EDP-514 for the treatment of hepatitis B, according to a press release.